Satellos Bioscience IncOTCQB:MSCLFView on Canadian Exchange
- LAST PRICE0.5900
- TODAY'S CHANGE (%)0.0050 (0.8547%)
- Bid / Lots0.5533/ 17
- Ask / Lots0.5950/ 178
- Open / Previous Close0.5900 / 0.5850
- Day Range
- 52 Week Range
- Volume5,333
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MSCLF |
|---|---|---|
| 04:00 ET | 5000 | 0.59 |
Nov 14, 2024
*DJ Satellos Appoints Stephanie Brown to Bd of Directors, from 7:02AM ET on Thursday Nov 14, 2024 by Dow Jones
7:02AM ET on Thursday Nov 14, 2024 by Dow JonesSatellos Appoints Stephanie Brown to Board of Directors, from 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 13, 2024
Press Release: Satellos Reports Q3 2024 Financial Results and Provides Clinical Update, from 7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 13, 2024 by Dow JonesSatellos Reports Q3 2024 Financial Results and Provides Clinical Update, from 7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 4, 2024
Satellos to Participate in November 2024 Investor Conferences, from 7:30AM ET on Monday Nov 04, 2024 by Dow Jones
7:30AM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Satellos Bioscience Inc | 96.4M | --- | --- |
Company Information
Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).
Contact Information
- Headquarters
- 200 Bay Street, Suite 2800TORONTO, ON, Canada M5J 2J1
- Phone
- 647-660-1780
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $96.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 113.4M |
Satellos Bioscience Inc does not pay a dividend. | |
Beta | 1.59 |
EPS | $-0.20 |
Book Value | $0.36 |
P/E Ratio | --- |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
